SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 20, 2013 (May 15, 2013)
VolitionRX Limited
(Exact name of registrant as specified in its charter)
|
|
|
Delaware | 000-30402 | 91-1949078 |
(State or other jurisdiction | (Commission File Number) | (IRS Employer |
of Incorporation) |
| Identification Number) |
|
#24-05 Shaw Centre Singapore 228208 |
|
| (Address of principal executive offices) |
|
| (201) 618-1750 |
|
| (Registrant’s Telephone Number) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
VOLITIONRX LIMITED
Form 8-K
Current Report
ITEM 5.02.
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS
Effective May 15, 2013, Satu Vainikka (“Dr. Vainikka”) resigned from all positions with the Company including, but not limited to, that of Director. Dr. Vainikka’s resignation did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise.
On May 16, 2013, the Company’s Board of Directors accepted Dr. Vainikka’s resignation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
| VOLITIONRX LIMITED
| ||
Date: May 20, 2013 | By: | /s/ Cameron Reynolds |
|
|
| Cameron Reynolds | |
|
| Chief Executive Officer & President | |